Elekta (OTCMKTS:EKTAY) Downgraded to “Strong Sell” Rating by Zacks Research

Elekta (OTCMKTS:EKTAY) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

Elekta Price Performance

Shares of EKTAY opened at $5.63 on Tuesday. The firm has a market capitalization of $2.08 billion, a PE ratio of -35.19 and a beta of 1.00. The company’s 50-day moving average is $5.99 and its 200-day moving average is $6.02. Elekta has a fifty-two week low of $4.35 and a fifty-two week high of $6.93. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.95 and a quick ratio of 0.73.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, May 28th. The company reported $0.06 EPS for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. The business had revenue of $521.00 million for the quarter. Equities analysts forecast that Elekta will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.